This TSX Stock Is Up Around 80% Since ‘Liberation Day’
When reciprocal tariffs were announced by U.S. President Donald Trump in early April, the markets tanked. And then, they quickly recovered after those fears calmed amid tariff pauses. What seemed initially like a huge blow to the markets would instead end up creating a fantastic buying opportunity.One of the best TSX stocks since the ‘Liberation Day’ tariff announcement has been Canadian tech company, Celestica (TSX:CLS)(NYSE:CLS). It is up around 80% since then. The stock has benefitted from the boom in artificial intelligence (AI) and a ramp up in tech spending. Its storage and networking products are integral in AI and machine learning data centers. Its broad customer base includes not just big tech companies, but also businesses in other sectors.As spending on AI has increased, Celestica has performed well. It last reported earnings on April 24, where it posted revenue totaling $2.65 billion – a 20% increase year over year. Over the trailing 12 months, the company has generated just over $10 billion in revenue. The one downside is that its margins aren’t all that strong, as Celestica’s profits over that stretch total just $422 million, for a profit margin of 4%.Currently, the stock trades at 42 times its trailing earnings while its forward price-to-earnings multiple is 30. Celestica stock is trading at all-time highs and isn’t a cheap buy anymore. But if you want to invest in a Canadian tech company that can benefit from the AI boom, this might be one to consider buying for your portfolio.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


